Small CDMO

Piramal Pharma Ltd.

PPLPHARMA

Market Cap
₹23,904 Cr.
P/E
0.00

Piramal Pharma Ltd.

  • Piramal Pharma
  • Cohance Lifesciences
  • Suven Life Sciences

FAQs on Piramal Pharma Ltd. Shareprice

Piramal Pharma has given better returns compared to its competitors.
Piramal Pharma has grown at ~23.88% over the last 3yrs while peers have grown at a median rate of -2.0%

Piramal Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Piramal Pharma is 34.15, while 3 year average PE is 201.
Also latest EV/EBITDA of Piramal Pharma is 30.57 while 3yr average is 24.03.

View FAQ's On Business

Growth Table

  • Piramal Pharma Ltd.
  • Cohance Lifesciences
  • Suven Life Sciences

Balance Sheet

  • Piramal Pharma Ltd.
  • Cohance Lifesciences
  • Suven Life Sciences

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Piramal Pharma Ltd.
  • Cohance Lifesciences
  • Suven Life Sciences

Cash Flow

  • Piramal Pharma Ltd.
  • Cohance Lifesciences
  • Suven Life Sciences

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Piramal Pharma Ltd.
  • Cohance Lifesciences
  • Suven Life Sciences

Quarterly Results

  • Piramal Pharma Ltd.
  • Cohance Lifesciences
  • Suven Life Sciences

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Piramal Pharma Ltd. Financials

Balance sheet of Piramal Pharma is moderately strong, But short term working capital might become an issue for this company.

The net debt of Piramal Pharma is decreasing.
Latest net debt of Piramal Pharma is ₹3,187 Crs as of Mar-26.
This is less than Mar-25 when it was ₹3,743 Crs.

The profit is oscillating.
The profit of Piramal Pharma is -₹325.94 Crs for Mar 2026, ₹91.13 Crs for Mar 2025 and ₹17.82 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Piramal Pharma latest dividend payout ratio is 20.35% and 3yr average dividend payout ratio is 51.0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Inventory

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech